The Technical Analyst
bluebird bio Inc [BLUE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
bluebird bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.78% $0.971
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 187.08 mill |
| EPS: | -0.630 |
| P/E: | -1.540 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 192.74 mill |
| Avg Daily Volume: | 8.53 mill |
| RATING 2024-04-23 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.540 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.26x |
| Company: PE -1.540 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.824 - 1.118 ( +/- 15.15%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Colvin Richard A | Buy | 199 000 | Stock Option (right to buy) |
| 2024-03-01 | Colvin Richard A | Sell | 6 770 | Common Stock |
| 2024-03-01 | Vittiglio Joseph | Buy | 199 000 | Stock Option (right to buy) |
| 2024-03-01 | Obenshain Andrew | Buy | 650 000 | Stock Option (right to buy) |
| 2024-03-04 | Obenshain Andrew | Sell | 6 095 | Common Stock |
| INSIDER POWER |
|---|
| 92.17 |
| Last 95 transactions |
| Buy: 3 237 593 | Sell: 214 711 |
Forecast:
16:00 - $0.974
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.974
Forecast 2: 16:00 - $0.974
Forecast 3: 16:00 - $0.974
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.971 (1.78% ) |
| Volume | 4.77 mill |
| Avg. Vol. | 8.53 mill |
| % of Avg. Vol | 55.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BLUE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $1.060 | N/A | Active |
|---|
BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-23 17:00:00 - Press Release
Class Action Filed Against Bluebird Bio, Inc. (blue) Seeking Recovery For Investors – Contact Levi & Korsinsky
New york, ny / accesswire / april 23, 2024 / if you suffered a loss on your bluebird bio, inc. (nasdaq:blue) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76745&wire=1 or contact joseph e. levi, esq.
2024-04-23 00:30:00 - Press Release
Shareholder Action Alert: The Schall Law Firm Encourages Investors In Bluebird Bio, Inc. With Losses Of $100,000 To Contact The Firm
Los angeles , april 23, 2024 /prnewswire/ -- the schall law firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, inc. ("bluebird" or "the company") (nasdaq: blue) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between april 24, 2023 and december 8, 2023, inclusive (the "class period"), are encouraged to contact the firm before may 28, 2024.
2024-04-22 11:45:00 - Press Release
Levi & Korsinsky Reminds Shareholders Of A Lead Plaintiff Deadline Of May 28, 2024 In Bluebird Bio Lawsuit - Blue
New york, ny / accesswire / april 22, 2024 / if you suffered a loss on your bluebird bio, inc. (nasdaq:blue) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76599&wire=1 or contact joseph e. levi, esq.
2024-04-22 11:45:00 - Press Release
Levi & Korsinsky Reminds Bluebird Bio Investors Of The Pending Class Action Lawsuit With A Lead Plaintiff Deadline Of May 28, 2024 - Blue
New york, ny / accesswire / april 22, 2024 / if you suffered a loss on your bluebird bio, inc. (nasdaq:blue) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76602&wire=1 or contact joseph e. levi, esq.
2024-04-22 07:30:00 - Press Release
Bluebird Bio, Inc. Sued For Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 28, 2024 To Discuss Your Rights - Blue
New york, ny / accesswire / april 22, 2024 / if you suffered a loss on your bluebird bio, inc. (nasdaq:blue) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=76531&wire=1 or contact joseph e. levi, esq.
Latest News
2024-04-16 15:06:04 - Zacks Investment Research
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
2024-04-15 08:15:00 - The Motley Fool
Is Bluebird Bio Stock a Buy?
Bluebird Bio is short on capital and has major new expenses to cover. Meanwhile, its pipeline of drug candidates is looking very weak.
2024-04-13 16:22:00 - The Motley Fool
Better Buy: Bluebird Bio Vs. Novavax
Bluebird Bio's most recently approved gene editing therapy looks highly promising. Novavax has generated decent revenue from its coronavirus vaccine.
2024-04-11 08:30:00 - The Motley Fool
Is This Beaten-Down Stock a Good Acquisition Target?
Bluebird Bio has accomplished something few gene-editing specialists have matched. However, the biotech could struggle to keep its operations running for a long time.
2024-03-29 05:20:00 - The Motley Fool
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
A top bank cut its price target on the shares by 25%, but it still feels they could more than double in price. Bluebird's fortunes have been mixed, to say the least, and it remains quite a risky investment.
2024-03-27 12:41:12 - Zacks Investment Research
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
2024-03-27 11:02:08 - Zacks Investment Research
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-03-25 16:05:00 - Business Wire
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET. To access the live conference call via telephone, please register at this link to receive a dial in number and unique PIN. The live webcast of the call may be accessed by visiting the “Events & Presentations” page within the Investors & Media section of the blue.
2024-03-19 08:46:05 - Zacks Investment Research
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.
2024-03-18 18:05:39 - The Motley Fool
Why Bluebird Bio Stock Flew Higher Than the Market Today
The commercial-stage biotech has secured a nine-figure loan facility. This potentially gives it access to as much as $175 million in debt funding.